StockData

Kymera Therapeutics vs Maze Therapeutics

KYMR and MAZE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KYMR and MAZE compare

Kymera Therapeutics is the larger company, worth 5.7 times as much as Maze Therapeutics ($10.4B against $1.8B).

Kymera Therapeutics scores higher on the StockData Score (9 against 4 for Maze Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKYMRMAZE
Size and price
Market cap$10.4B$1.8B
Share price$121.52$32.87
Change, 1 year87.1%1.0%
Change, 5 years126%–
Beta (5Y)0.590.69
Employees238141
StockData Score
Total score9 (better)4
Valuation score00
Growth score1 (better)0
Performance score2 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/S101×–
P/B6.4×4.0× (better)
FCF yield−2.8% (better)−5.9%
Fair value$37.15–
Margin of safety−227%–
Growth
Revenue growth (TTM)134%–
Revenue growth, 5Y average2.9%–
Profitability
Gross margin0.00%–
Operating margin−396%–
Net margin−342%–
FCF margin−283%–
Return on equity−27.3% (better)−37.3%
Return on invested capital−59.0% (better)−292%
Financial health
Debt / equity0.000.09 (better)
Current ratio11.1318.31 (better)
Altman Z-score39.62 (better)12.48
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions114%105%
Held by insiders38.3%16.9%
Insider net buying, 12 months−$301M−$25.0M (better)
Superinvestors holding–1
Short interest, % of float16.0%14.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.